PuSH - Publikationsserver des Helmholtz Zentrums München

Manapov, F.* ; Nieto, A.* ; Käsmann, L.* ; Taugner, J.* ; Kenndoff, S.* ; Flörsch, B.* ; Guggenberger, J.* ; Hofstetter, K.* ; Kröninger, S.* ; Lehmann, J.* ; Kravutske, H.* ; Pelikan, C. ; Belka, C.* ; Eze, C.*

Five years after PACIFIC: Update on multimodal treatment efficacy based on real-world reports.

Expert Opin. Investig. Drugs 32, 187-200 (2023)
DOI PMC
INTRODUCTION: The growing body of real-life data on maintenance treatment with durvalumab suggests that immunological markers of the cancer-host interplay may have significant effects on the efficacy of multimodal therapy in patients with unresectable stage III NSCLC. AREAS COVERED: We summarize real-world clinical data regarding this new tri-modal approach and report on potential biomarker landscape. EXPERT OPINION: The obvious question posed in this context of a very heterogeneous inoperable stage III NSCLC disease is: How can we augment an ability to predict checkpoint inhibition success or failure? Which tools and biomarkers, which clinical metadata and genetic background are relevant and feasible? No single biomarker will ever fully dominate the unresectable stage III NSCLC space, so we advocate multilevel and multivariate analysis of biomarkers. In this particular opinion piece, we explore the impact of PD-L1 expression on tumor cells, neutrophil-to-lymphocyte ratio, EGFR and STK11 mutational status, interferon-gamma signature, and tumor-infiltrating lymphocytes among others.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Pd-l1 ; Checkpoint Inhibition ; Durvalumab ; Interferon Gamma ; Mutational Landscape ; Non-small Cell Lung Cancer ; Tumor Microenvironment ; Tumor-infiltrating Lymphocytes; Cell Lung-cancer; Local-regional Control; Open-label; Concurrent Chemoradiotherapy; Predictive Biomarkers; Adjuvant Durvalumab; Pd-l1 Expression; Nsclc; Chemoradiation; Immunotherapy
ISSN (print) / ISBN 1354-3784
e-ISSN 1744-7658
Zeitschrift Expert Opinion on Investigational Drugs
Quellenangaben Band: 32, Heft: 3, Seiten: 187-200 Artikelnummer: , Supplement: ,
Verlag Taylor & Francis
Verlagsort 2-4 Park Square, Milton Park, Abingdon Or14 4rn, Oxon, England
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Virology (VIRO)